Cardiome Pharma Corp (NASDAQ:CRME)

CAPS Rating: 1 out of 5

Life sciences company focused on developing proprietary drugs to treat or prevent cardiovascular diseases. Current efforts are focused on the treatment of atrial arrhythmias and congestive heart failure.

Recs

1
Player Avatar genedom (98.11) Submitted: 3/10/2014 3:32:41 AM : Outperform Start Price: $8.68 CRME Score: -5.74

A four-bagger in one year.

Featured Broker Partners


Advertisement